Study Details

A Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FMS-like tyrosine kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03730012

Astellas Study ID

The unique identification code given by the study sponsor.

2215-CL-1101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Condition

Leukemia - AML

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

gilteritinib

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jun 2019 - Jun 2021

Masking

None (Open Label)

Enrollment number

11

Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FMS-like tyrosine kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Northwestern University

Chicago, United States, 60611

The Ohio State University Comprehensive Cancer Center (OSUCCC)

Columbus, United States, 43210

Vanderbilt Ingram Cancer Center

Nashville, United States, 37232

Medical University of South Carolina (MUSC) - Hollings Cancer Center (HCC)

Charleston, United States, 29425

Roswell Park Cancer Institute (RPCI)

Buffalo, United States, 14263

Weill Cornell Medical College

New York, United States, 10065

Medical College of Wisconsin

Milwaukee, United States, 53226

University of Kentucky

Lexington, United States, 40536

University of Chicago

Chicago, United States, 60037

University of Texas MD Anderson

Houston, United States, 77030

Columbia University Medical Center

New York, United States, 10032

Simmons Comprehensive Cancer Center

Dallas, United States, 75390

Ronald Reagan UCLA Medical Center

Los Angeles, United States, 90095